Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Stoke Therapeutics (STOK) Equity Ratio (2021 - 2025)

Stoke Therapeutics has reported Equity Ratio over the past 5 years, most recently at 0.84 for Q4 2025.

  • For Q4 2025, Equity Ratio changed 0.12% year-over-year to 0.84; the TTM value through Dec 2025 reached 0.84, changed 0.12%, while the annual FY2025 figure was 0.84, 0.12% changed from the prior year.
  • Equity Ratio for Q4 2025 was 0.84 at Stoke Therapeutics, down from 0.86 in the prior quarter.
  • Over five years, Equity Ratio peaked at 0.91 in Q4 2021 and troughed at 0.68 in Q1 2024.
  • A 5-year average of 0.78 and a median of 0.76 in 2022 define the central range for Equity Ratio.
  • Biggest five-year swings in Equity Ratio: decreased 20.82% in 2022 and later rose 25.79% in 2025.
  • Year by year, Equity Ratio stood at 0.91 in 2021, then decreased by 20.82% to 0.72 in 2022, then dropped by 3.2% to 0.7 in 2023, then grew by 20.69% to 0.84 in 2024, then dropped by 0.12% to 0.84 in 2025.
  • Business Quant data shows Equity Ratio for STOK at 0.84 in Q4 2025, 0.86 in Q3 2025, and 0.87 in Q2 2025.